. Author manuscript; available in PMC: 2011 Oct 6.

Published in final edited form as: Clin Pharmacol Ther. 2007 Mar;81(3):346–353. doi: 10.1038/sj.clpt.6100082

Table 1.

d-MPH arithmetic mean (SD%), least-square geometric mean (90% CI) and geometric mean ratio of pharmacokinetic parameters for normal subjects (n=19) as compared with the poor metabolizer Subject D

	MPH–Ethanol	Ethanol–MPH	MPH
	AUC_inf	AUC_inf	AUC^*_inf
Mean (SD%)	105.2 (22.3)^*	102.8 (18.65)^*	82.9 (26.2)
GeoMean ratio	102.1	99.0	80.2 (—)
GeoMean (90% CI)	1.27 (1.19–1.35)	1.23 (1.15–1.32)	—
Subject D	267.6	224.2	208.7
	C _max	C _max	C _max ^*
Mean (SD%)	21.5 (31.7)^*	21.4 (22.7)^*	15.3 (22.0)
GeoMean ratio	20.7	21.0	15.2 (—)
GeoMean (90% CI)	1.37 (1.23–1.52)	1.39 (1.24–1.56)	—
Subject D	41.0	39.4	36.7
	T _max	T _max	T _max
Mean (SD%)	2.0 (31.2)	2.2 (41.5)	2.3 (32.7)
Subject D	1.5	2.0	3.0
	t _1/2	t _1/2	t _1/2
Mean (SD%)	3.0 (18.8)	2.9 (21.5)	2.8 (14.3)
Subject D	8.2	5.0	5.4

AUC_inf, area under the concentration–time curve; CI, confidence interval; CV, coefficient of variance; MPH, methylphenidate; SD, standard deviation. Subjects received MPH (0.3 mg/kg) 30min before ethanol (0.6 g/kg) or the ethanol 30 min before MPH, or only MPH.

Significantly different from test: (P<0.0001).